Ten Years of Human Papillomavirus Vaccination in the United States

Academic Pediatrics

Volumn 18, Issue 2, 2018, Pages S3-S10

  Markowitz, Lauri E ^a   Gee, Julianne ^b   Chesson, Harrell ^c   Stokley, Shannon ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

human papillomavirus; human papillomavirus vaccine; immunization program

Indexed keywords

WART VIRUS VACCINE;

COMPLEX REGIONAL PAIN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FAINTNESS; FEVER; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; INTERPERSONAL COMMUNICATION; PAPILLOMAVIRUS INFECTION; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; REVIEW; UNITED STATES; VACCINATION; VACCINATION COVERAGE; VACCINE FAILURE; VENOUS THROMBOEMBOLISM; ADOLESCENT; ANUS TUMOR; CHILD; COMPLICATION; FEMALE; MALE; OROPHARYNX TUMOR; PENIS TUMOR; PREVENTIVE HEALTH SERVICE; UTERINE CERVIX TUMOR; VAGINA TUMOR; VULVA TUMOR;

ADOLESCENT; ANUS NEOPLASMS; CHILD; FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION COVERAGE; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 85042786974     PISSN: 18762859     EISSN: 18762867     Source Type: Journal    
DOI: 10.1016/j.acap.2017.09.014     Document Type: Review

References (75)

1. Forman, D., de Martel, C., Lacey, C.J., et al. Global burden of human papillomavirus and related diseases. Vaccine 30:suppl 5 (2012), F12–F23.
2. Centers for Disease Control and Prevention, Number of HPV-associated cancer cases per year. Available at: https://www.cdc.gov/cancer/hpv/statistics/cases.htm. (Accessed 10 August 2017)
3. Saraiya, M., Unger, E.R., Thompson, T.D., et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst, 107, 2015, djv086.
4. Schiller, J.T., Castellsague, X., Garland, S.M., A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30:suppl 5 (2012), F123–F138.
5. Markowitz, L.E., Dunne, E.F., Saraiya, M., et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63 (2014), 1–30.
6. Petrosky, E., Bocchini, J.A. Jr., Hariri, S., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 64 (2015), 300–304.
7. Markowitz, L.E., Dunne, E.F., Saraiya, M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007), 1–24.
8. Kroger, A.T., Atkinson, W.L., Marcuse, E.K., et al., Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) (errata in: 2006;55:1303, Pediatrics 2007;119:1008 and 2007;56:256). MMWR Recomm Rep 55 (2006), 1–48.
9. Centers for Disease Control and Prevention (CDC), FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59 (2010), 626–629.
10. Centers for Disease Control and Prevention (CDC), FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59 (2010), 630–632.
11. Centers for Disease Control and Prevention (CDC), Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1705–1708.
12. Meites, E., Kempe, A., Markowitz, L.E., Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 65 (2016), 1405–1408.
13. Palefsky, J.M., Giuliano, A.R., Goldstone, S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365 (2011), 1576–1585.
14. Fairley, C.K., Zou, H., Zhang, L., et al. Human papillomavirus vaccination in men who have sex with men - what will be required by 2020 for the same dramatic changes seen in heterosexuals. Sex Health 14 (2017), 123–125.
15. Kim, J.J., Goldie, S.J., Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J, 339, 2009, b3884.
16. Chesson, H.W., Ekwueme, D.U., Saraiya, M., et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29 (2011), 8443–8450.
17. Elbasha, E.H., Dasbach, E.J., Impact of vaccinating boys and men against HPV in the United States. Vaccine 28 (2010), 6858–6867.
18. Joura, E.A., Giuliano, A.R., Iversen, O.E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
19. Iversen, O.E., Miranda, M.J., Ulied, A., et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 316 (2016), 2411–2421.
20. Markowitz, L.E., Meites, E., Unger, E.R., Two vs three doses of human papillomavirus vaccine: new policy for the second decade of the vaccination program. JAMA 316 (2016), 2370–2372.
21. Sanders, G.D., Taira, A.V., Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 (2003), 37–48.
22. Taira, A.V., Neukermans, C.P., Sanders, G.D., Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 (2004), 1915–1923.
23. Goldie, S.J., Kohli, M., Grima, D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004), 604–615.
24. Elbasha, E.H., Dasbach, E.J., Insinga, R.P., Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007), 28–41.
25. Kim, J.J., Goldie, S.J., Health and economic implications of HPV vaccination in the United States. N Engl J Med 359 (2008), 821–832.
26. Chesson, H.W., Ekwueme, D.U., Saraiya, M., et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14 (2008), 244–251.
27. Kim, J.J., Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10 (2010), 845–852.
28. Brisson, M., Laprise, J.F., Chesson, H.W., et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst, 108, 2016, djv282.
29. Laprise, J.F., Markowitz, L.E., Chesson, H.W., et al. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 214 (2016), 685–688.
30. CDC, Centers for Disease Control and Prevention. Vaccines for Children Program (VFC). Available at: http://www.cdc.gov/vaccines/programs/vfc/index.html. (Accessed 18 May 2017)
31. Walker, T.Y., Elam-Evans, L.D., Singleton, J.A., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016. MMWR Morb Mortal Wkly Rep 66 (2017), 874–882.
32. Ng, J., Ye, F., Roth, L., et al. Human papillomavirus vaccination coverage among female adolescents in managed care plans - United States, 2013. MMWR Morb Mortal Wkly Rep 64 (2015), 1185–1189.
33. Jeyarajah, J., Elam-Evans, L.D., Stokley, S., et al. Human papillomavirus vaccination coverage among girls before 13 years: a birth year cohort analysis of the National Immunization Survey-Teen, 2008-2013. Clin Pediatr 55 (2016), 904–914.
34. Stewart, A.M., Mandating HPV vaccination–private rights, public good. N Engl J Med 356 (2007), 1998–1999.
35. Mello, M.M., Abiola, S., Colgrove, J., Pharmaceutical companies’ role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 102 (2012), 893–898.
36. Moss, J.L., Reiter, P.L., Truong, Y.K., et al. School entry requirements and coverage of nontargeted adolescent vaccines. Pediatrics, 138, 2016, e20161414.
37. Washburn, T., Devi Wold, A., Raymond, P., et al. Current initiatives to protect Rhode Island adolescents through increasing HPV vaccination. Hum Vaccin Immunother 12 (2016), 1633–1638.
38. Smulian, E.A., Mitchell, K.R., Stokley, S., Interventions to increase HPV vaccination coverage: a systematic review. Hum Vaccin Immunother 12 (2016), 1566–1588.
39. Holman, D.M., Benard, V., Roland, K.B., et al. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 168 (2014), 76–82.
40. Allison, M.A., Hurley, L.P., Markowitz, L., et al. Primary care physicians’ perspectives about HPV vaccine. Pediatrics, 137, 2016, e20152488.
41. CDC, Centers for Disease Control and Prevention. Human papillomavirus (HPV). For clinicians. Available at: https://www.cdc.gov/hpv/hcp/index.html. (Accessed 18 May 2017)
42. Lindley, M.C., Jeyarajah, J., Yankey, D., et al. Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls. Hum Vaccin Immunother 12 (2016), 1519–1527.
43. Healy, C.M., Montesinos, D.P., Middleman, A.B., Parent and provider perspectives on immunization: are providers overestimating parental concerns?. Vaccine 32 (2014), 579–584.
44. Gee, J., Weinbaum, C., Sukumaran, L., et al. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother 12 (2016), 1406–1417.
45. Descamps, D., Hardt, K., Spiessens, B., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 5 (2009), 332–340.
46. Moreira, E.D. Jr., Block, S.L., Ferris, D., et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics, 138, 2016, e20154387.
47. Guardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant) Suspension for intramuscular injection [prescribing information], 2011, Merck & Co, Whitehouse Station, NJ.
48. Cervarix (human papillomavirus bivalent [types 16, 18] vaccine, recombinant) Suspension for intramuscular injection [prescribing information]. Rixensart, Belgium; GlaxoSmithKline.
49. Centers for Disease Control and Prevention (CDC), Syncope after vaccination–United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 57 (2008), 457–460.
50. CDC, Centers for Disease Control and Prevention. Frequently asked questions about HPV vaccine safety. Available at https://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html. (Accessed 18 May 2017)
51. Stokley, S., Jeyarajah, J., Yankey, D., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb Mortal Wkly Rep 63 (2014), 620–624.
52. World Health Organization, Meeting of the Global Advisory Committee on Vaccine Safety, 7-8 June 2017. Wkly Epidemiol Rec 92 (2017), 393–404.
53. IOM (Institute of Medicine). Adverse effects of vaccines: Evidence and causality. 2012, The National Academies Press, Washington, DC.
54. Gollust, S.E., LoRusso, S.M., Nagler, R.H., et al. Understanding the role of the news media in HPV vaccine uptake in the United States: synthesis and commentary. Hum Vaccin Immunother 12 (2016), 1430–1434.
55. Katie Couric show on HPV vaccine sparks backlash, 2013. Available at: http://www.cbsnews.com/news/katie-couric-show-on-hpv-vaccine-sparks-backlash/. (Accessed 18 May 2017)
56. Briones, R., Nan, X., Madden, K., et al. When vaccines go viral: an analysis of HPV vaccine coverage on YouTube. Health Commun 27 (2012), 478–485.
57. Bednarczyk, R.A., Davis, R., Ault, K., et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 130 (2012), 798–805.
58. Hansen, B.T., Kjaer, S.K., Arnheim-Dahlstrom, L., et al. Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: evidence from a large survey of Nordic women. Vaccine 32 (2014), 4945–4953.
59. Markowitz, L.E., Hariri, S., Lin, C., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 208 (2013), 385–393.
60. Markowitz, L.E., Liu, G., Hariri, S., et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137, 2016, e20151968.
61. Oliver, S., Unger, E.R., Lewis, R., et al. Prevalence of human papillomavirus among females after vaccine introduction – National Health and Nutrition Examination Survey, United States, 2003-2014. J Infect Dis 216 (2017), 594–603.
62. Dunne, E.F., Naleway, A., Smith, N., et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012. J Infect Dis 212 (2015), 1970–1975.
63. Kahn, J.A., Brown, D.R., Ding, L., et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 130 (2012), e249–e256.
64. Kahn, J.A., Widdice, L.E., Ding, L., et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis 63 (2016), 1281–1287.
65. Flagg, E.W., Schwartz, R., Weinstock, H., Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 103 (2013), 1428–1435.
66. Perkins, R.B., Legler, A., Hanchate, A., Trends in male and female genital warts among adolescents in a safety-net health care system 2004-2013: correlation with introduction of female and male human papillomavirus vaccination. Sex Transm Dis 42 (2015), 665–668.
67. Gargano JW, Johnson M, Griffin MR, et al. Trends in high-grade cervical lesions and cervical cancer screening in five states, 2008–2014. Presented at the 31st International Papillomavirus Conference; February 28-March 4, 2017; Cape Town, South Africa.
68. Benard, V.B., Castle, P.E., Jenison, S.A., et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 3 (2017), 833–837.
69. Flagg, E.W., Torrone, E.A., Weinstock, H., Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007-2014. Am J Public Health 106 (2016), 2211–2218.
70. Drolet, M., Benard, E., Boily, M.C., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
71. Mesher, D., Soldan, K., Lehtinen, M., et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 22 (2016), 1732–1740.
72. Saslow, D., Solomon, D., Lawson, H.W., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 137 (2012), 516–542.
73. Moyer, V.A., Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156 (2012), 880–891.
74. Hariri, S., Johnson, M.L., Bennett, N.M., et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 121 (2015), 2775–2781.
75. Healthy People 2020. Immunization and infectious disease. Healthy People 2020. Immunization and Infectious Disease, 2011 Available at: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives. Accessed May 18, 2017.